Printer Friendly

Mesenchymal Progenitors Can Be Grown Without Animal Compounds: Big Stride Forward In Creation Of Clinical-Grade Bone.

New York, N.Y., January 15, 2019 -- A team of scientists here has made valuable progress toward creating clinical-grade cells for treatment of bone disease and injury.

In their study, the team identified two types of growth media that could support effective expansion of mesenchymal progenitor (MP) cells from stem cells in a clinically compatible, Good Manufacturing Practice (GMP) setting.

MP cells are important because they resemble mesenchymal stem cells (MSCs).

MSCs can go on to form a variety of cell types, including bone cells, cartilage cells, muscle cells, and fat cells, and can modulate the behavior of many other types of cell types in the body.

They are a frequent target for cell therapies in which healthy cells are introduced into the body to treat diseases or reconstruct tissues and organs.

However, MSCs are often scarce and do not expand well enough to provide the amount of cells needed for an effective therapy. MP cells, on the other hand, can be produced in large numbers for each patient when generated from induced pluripotent stem cells (iPSCs), and therefore hold extraordinary promise for the treatment of blood, heart, and immune diseases as well as repair of damaged bone and cartilage.

"MP cells have been derived from iPSCs before, but never in a growth medium that does not contain animal-derived compounds," said lead researcher Giuseppe Maria de Peppo of the New York Stem Cell Foundation (NYSCF) Research Institute. "We are glad to see that MP cells grown in GMP-compliant media showed the same biological and functional properties as those grown in research-grade media that contains animal products. The results will help us plan for movement of these cells out of the lab and into the clinic."

The researchers compared MP cells grown in a medium supplemented with fetal bovine serum, a product derived from cows, to MP cells grown in two different media without animal products (referred to as "xeno-free"): one supplemented with human platelet lysates and one commercial high-performance GMP medium (Allegro Unison Medium).

While MP cells grown in the xeno-free and GMP media showed slightly different cell morphology, expansion potential, gene expression, and cytokine profile than those grown in the medium containing fetal bovine serum, the cells were healthy and functional in these new conditions.

Collectively, the results show promise for the eventual application of MP cells in cellular therapies.

Citation: Madison McGrath et al., GMP-compatible and xeno-free cultivation of mesenchymal progenitors derived from human-induced pluripotent stem cells. Stem Cell Research & Therapy, 2019; 10 (1) DOI:10.1186/s13287-018-1119-3


Contact: Giuseppe Maria de Peppo,

COPYRIGHT 2019 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Basic Research
Publication:Stem Cell Research News
Date:Jan 28, 2019
Previous Article:Discovery Opens Doors To New Therapy For Most ALS Patients.
Next Article:Mesenchymal Stems Cells Play Vital Role In Repair Of Damaged Organs.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |